Inclusion Criteria:  Measurable disease defined as at least one unidimensional measurable lesion by computed tomography (CT) or magnetic resonance imaging (MRI). Must have at least one lesion > 2 cm within the target perfused volume. At least one lesion must meet the definition of target lesion as defined by RECIST 1.1 or mRECIST. Total linear length of all lesions must be ≤ 9 cm. Must have preservation of >700cc of normal liver parenchyma outside of treated volume. Hypervascular lesions on CT scan with 99mTC MAA SPECT/CT T:N ratio 3:1 or higher and Hypervascular on CBCT. Life expectancy of ≥ 6 months. ≥ 18 years old.  Exclusion Criteria:  Hemoglobin ≤ 85 mg/L. Platelet count < 50,000/microliter or prothrombin (PT) activity > 50% normal INR > 1.4 (if anticoagulated, reversal must be achieved prior to any angiographic procedures). ALT > 2.5x upper limit AST > 2.5x upper limit For HCC subjects, Bilirubin ≥ 2 mg/dL. For mCRC subjects, Bilirubin ≥ 1.2 mg/dL. eGFR ≤ 60 mL/min/1.73 m2. Portal vein thrombosis (PVT). Estimated lung dose > 30 Gy as calculated using the lung shunt % and partition model.